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Abstract
Background: Poor medication adherence is a major challenge in asthma, and objective assessment of inhaler adherence is
needed. The InspirerMundi app aims to monitor adherence while providing a positive experience through gamification and social
support.
Objective: This study aimed to evaluate the feasibility and acceptability of the InspirerMundi app to monitor medication
adherence in adolescents and adults with persistent asthma (treated with daily inhaled medication).
Methods: A 1-month mixed method multicenter observational study was conducted in 26 secondary care centers from Portugal
and Spain. During an initial face-to-face visit, physicians reported patients’ asthma therapeutic plan in a structured questionnaire.
During the visits, patients were invited to use the app daily to register their asthma medication intakes. A scheduled intake was
considered taken when patients registered the intake (inhaler, blister, or other drug formulation) by using the image-based
medication detection tool. At 1 month, patients were interviewed by phone, and app satisfaction was assessed on a 1 (low) to 5
(high) scale. Patients were also asked to point out the most and least preferred app features and make suggestions for future app
improvements.
Results: A total of 107 patients (median 27 [P25-P75 14-40] years) were invited, 92.5% (99/107) installed the app, and 73.8%
(79/107) completed the 1-month interview. Patients interacted with the app a median of 9 (P25-P75 1-24) days. At least one
medication was registered in the app by 78% (77/99) of patients. A total of 53% (52/99) of participants registered all prescribed
inhalers, and 34% (34/99) registered the complete asthma therapeutic plan. Median medication adherence was 75% (P25-P75
25%-90%) for inhalers and 82% (P25-P75 50%-94%) for other drug formulations. Patients were globally satisfied with the app,
with 75% (59/79) scoring ≥4,; adherence monitoring, symptom monitoring, and gamification features being the most highly
scored components; and the medication detection tool among the lowest scored. A total of 53% (42/79) of the patients stated that
the app had motivated them to improve adherence to inhaled medication and 77% (61/79) would recommend the app to other
patients. Patient feedback was reflected in 4 major themes: medication-related features (67/79, 85%), gamification and social
network (33/79, 42%), symptom monitoring and physician communication (21/79, 27%), and other aspects (16/79, 20%).
Conclusions: The InspirerMundi app was feasible and acceptable to monitor medication adherence in patients with asthma.
Based on patient feedback and to increase the registering of medications, the therapeutic plan registration and medication detection
tool were redesigned. Our results highlight the importance of patient participation to produce a patient-centered and engaging
mHealth asthma app.
(JMIR Mhealth Uhealth 2021;9(5):e26442) doi: 10.2196/26442
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Background
Inhaled preventive medications are the cornerstone of effective
asthma treatment, reducing symptoms and exacerbations [1].
Yet in the last three decades, rates of adherence among patients
with asthma remained unchanged, ranging from 19% to 64%
[2]. Poor medication adherence is thus a major challenge in
asthma [2,3] and is a leading driver of poor health outcomes,
including emergency department visits, hospitalizations, and
increased health care costs [4]. Based on this significant burden,
medication adherence is a top priority for disease management
[1] and policy agendas [5,6].
Research efforts to tackle medication nonadherence have not
led to the much needed improvement [7]. Behavioral and
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educational interventions had modest effects, possibly because
most propose one-size-fits-all solutions for distinct
nonadherence phenotypes (erratic, unwitting, intelligent) [8].
These interventions also failed to consider facilitators for
real-world implementation [8]. The objective measurement of
inhaler adherence is another major problem [9]. Electronic
monitoring devices are available but their dissemination in
real-world practice is difficult and costly [10].
Mobile health (mHealth) technologies may be promising to
support medication adherence as they are easily integrated into
patients’ everyday lives, especially if using only smartphone
embedded sensors [11]. mHealth allows the combination of
computation, communication, and interactive display that makes
it possible to use gamification and peer support tools with the
potential to inspire behavior changes and offer treatment
adherence quantification [11,12]. Moreover, patients with
asthma have increasingly high smartphone ownership levels
and are interested in using disease-specific apps [13,14].
The InspirerMundi app development was grounded in previous
research and cooperation with patients with asthma and
physicians [15]. The app aims to transform adherence to inhalers
into a positive experience through gamification and social
support while allowing for verified inhaler adherence
monitoring. The concept and gameplay of the InspirerMundi
app derive from promoting user social interaction in a quest to
help other users increase inhaler adherence (while being an
example of good adherence). The user’s goal is to become an
Inspirer to increase the sphere of positive influence by coaching
an expanding network of Warriors (as Warriors progress and
keep good medication adherence, they can become Inspirers
themselves). The most innovative app technology is the
medication detection tool based on advanced processing of
inhaler images captured with the smartphone camera [16].
The app development process was iterative with real-life tests
and improvements based on user feedback. The first version
was previously tested in a usability study, and improvements
were made [17]. It is believed that the InspirerMundi app is
innovative in measuring and improving medication adherence
in patients with asthma. Before studying its effectiveness,
however, there is a need for feasibility studies to monitor its
use and evaluate its acceptability. Thus, this study aimed to
evaluate the feasibility and acceptability of the InspirerMundi
app to monitor medication adherence in adolescents and adults
with asthma.
Methods
Study Design
A multicenter observational study with one initial face-to-face
visit and a telephone interview at 1 month was conducted [18].
During the study, an additional telephone interview at 1 week
for additional data collection and 3 text messages (at 2, 14, and
21 days) to promote app engagement were added. A convenience
sample of adolescents and adults with persistent asthma was
recruited between November 2017 and April 2019 at 26 allergy,
pulmonology, and pediatric secondary care centers in Portugal
(North, Centre, Lisbon, Algarve, Azores, and Madeira regions)
and Spain (Galicia and Madrid regions). Centers were asked to
recruit at least 2 patients as a minimum of 20 adolescents and
20 adults were targeted [19,20]. The study protocol was
approved by the ethics committees of all participating centers.
The study was conducted in accordance with the ethical
standards established in the Declaration of Helsinki. Eligible
patients were approached by physicians during medical visits
and invited to participate in a study on the use of an app to
register their asthma medication daily intake. Written informed
consent was obtained before enrollment in the study. Adult
patients signed a consent form; adolescents signed an assent
form and a parental consent form was also obtained. The study
is reported according to STROBE (Strengthening the Reporting
of Observational Studies in Epidemiology) guidelines [21].
Participants
Patients were included if they (1) had a previous medical
diagnosis of persistent asthma, (2) were at least 13 years old
(13 to 17 years for adolescents; 18 years and older for adults),
(3) were able to use mobile apps and had access to a mobile
device with internet access, and (4) had an active prescription
for a daily inhaled controller medication for asthma. All inhaled
controller treatments were allowed, and there was no change in
any prescribed medication as a result of the participation in this
study. Patients were excluded if they had a diagnosis of a
chronic lung disease other than asthma or a diagnosis of another
significant chronic condition with possible interference with
the study aims.
InspirerMundi App
The InspirerMundi app is focused on supporting patient
medication management and promoting treatment adherence.
The InspirerMundi app is grounded on the Fogg behavior model,
which states that a behavior is performed when 3 elements
converge in a given moment: motivation, ability, and trigger
(Table 1) [22]. The app includes registration of the therapeutic
plan, which activates notifications when a medication is due
(trigger) and allows recording of performed intakes through a
medication detection tool that uses the smartphone camera. The
medication detection tool is based on advanced image processing
techniques and identifies the inhaler through template matching
[15]. At the time of the study, the tool could detect 6 inhaler
devices containing numeric dose counters (Diskus/Accuhaler
[GlaxoSmithKline PLC], Ellipta [GlaxoSmithKline PLC],
Flutiform pMDI [Napp Pharmaceuticals LTD],
Novolizer/Genuair [AstraZeneca], Spiromax [Teva
Pharmaceutical Industries LTD], Turbohaler [AstraZeneca]).
The medication detection tool can also be applied to other types
of inhalers or other drug formulations (eg, blister or other
recipients) but the template matching feature cannot. In the app
version tested, a scheduled intake was considered taken when
patient presented the medication (inhaler, blister, or other drug
formulation) to the detection tool (10 seconds). Adherence
statistics are provided to the user in the form of circular progress
graphs (motivator: self-monitoring; ability: simplifies adherence
measurement). Besides planned medication, the user may also
record relief medication intake events that are not considered
for treatment adherence assessment. Physician involvement is
also supported by providing the user with the possibility of
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sharing the registered therapeutic plan and respective adherence
data. Medication management is supported by a timeline that
reflects the registered therapeutic plan. The timeline also
includes events related to gamification and symptom monitoring.
Patients are invited to answer 3 types of questionnaires related
to their symptoms and asthma control: daily questionnaire (daily
after 6 PM), weekly questionnaire (once per week), and Control
of Allergic Rhinitis and Asthma Test (CARAT, by default once
per month but can be personalized by the patient to weekly or
every 2 weeks) [23] (motivator: self-monitoring, personalization;
ability: simplifies assessment of asthma control). CARAT total
score is calculated by summing the 10 questions resulting in a
range of 0 to 30 points. A score >24 indicates good disease
control [24], and this classification is presented to the patient
(motivator: anticipation/hope of a health improvement). This
questionnaire is available in multiple languages, and its
psychometric properties are established [25].
The concept and gamification dynamics are twofold:
achievement challenges and social interaction (motivator:
belonging, social acceptance, app as a social actor). Gameplay
and mechanics included in the app derive from achievement
points and badges (triggers) and by promoting social interaction
based on a story of evolving from a Warrior (beginner player,
level 1) to an Inspirer (advanced player, an example of good
adherence, available from level 10 onward), who can motivate
Warriors to improve adherence (motivators: cooperation,
competition, recognition). The main components that support
the game are points earned when users take certain actions
(motivator: sensation of pleasure, positive reward) such as
registering a new medication, registering scheduled medication
intakes at the right time, answering symptom questionnaires,
or getting a positive assessment from other users in their
network. Registering events of relief medication does not
generate additional points. When registering a relief medication
intake, patients are invited to rate the severity of symptoms
experienced on a visual analog scale (VAS; 0 to 100) and report
any use of health care. Another encouragement for user
interaction is the attribution of virtual badges (12 available;
motivator: sensation of pleasure, positive reward). Whenever
the user reaches a certain goal (eg, Role Model badge when the
user links to the first Warrior) or does something special (eg,
Big Influencer badge when the user reaches 5 Warriors), they
will be rewarded and get a virtual badge for their actions. The
app, developed in Portuguese, English, and Spanish, is available
in the App Store (version 1.1) and Google Play (versions 1.1.x);
app is only available for download in Portugal and Spain.
Screenshots of the app version tested (version 1.1) are presented
in Figure 1, and videos are available [26-29].
Figure 1. InspirerMundi app screenshots (version 1.1).
JMIR Mhealth Uhealth 2021 | vol. 9 | iss. 5 | e26442 | p. 4https://mhealth.jmir.org/2021/5/e26442
(page number not for citation purposes)
Jácome et alJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
Table 1. Elements of the Fogg behavior model in the InspirerMundi app.
App componentApp featureElements and description of the Fogg behavior
model
Trigger
Medication managementSignal: notification appears when a medication intake is dueFacilitator of adherence
Medication managementSignal: intake icon flashes when a medication intake is dueFacilitator of medication intake registration
CARATa, daily questionnaire, and
weekly questionnaire
Signal: questionnaire icon flashes when a response is dueFacilitator of asthma control assessment
Medication management, gamifica-
tion
Signal: buzzes when an Inspirer sends a medication reminder
to a Warrior
Facilitator of adherence
GamificationSignal: icon of message appears (exchange between Inspirer
and Warrior)
Facilitator of adherence
Ability
Medication managementAdherence statistics: circular progress graphSimplifies adherence measurement
CARATAsthma control classificationSimplifies assessment of asthma control
Motivator
Medication managementAdherence statistics: circular progress graphSelf-monitoring
CARATPersonalized frequencySelf-monitoring, personalization
CARATAsthma control classificationAnticipation/hope of a health improvement
GamificationSocial interactionBelonging, social acceptance, app as a so-
cial actor
GamificationInspirer and Warrior playersCooperation, competition, recognition
GamificationPointsSensation of pleasure, positive reward
GamificationVirtual badgesSensation of pleasure, positive reward
aCARAT: Control of Allergic Rhinitis and Asthma Test.
Data Collection
During the initial face-to-face visit, physician recorded if it was
a first or follow-up appointment; patient’s asthma control
according to the Global Initiative for Asthma (GINA) [1];
number of exacerbations in the previous year (defined as
episodes of progressive increase in shortness of breath, cough,
wheezing, and/or chest tightness requiring a change in
maintenance therapy [30]); and use of health care resources in
the previous year (ie, number of unscheduled medical visits to
primary care, secondary care, or emergency department and
number of hospital admissions). Physician also recorded
patient’s current asthma treatment, including inhaled and oral
medication, allergen immunotherapy, and biologic therapy. At
the visit, patient answered written questionnaires on
demographic data (age, gender, BMI, smoking habits),
adherence to inhaled controller asthma medication during the
previous week, and perception of the correctness of inhaler
technique (using a 100 mm VAS), asthma control during the
previous 4 weeks (using CARAT), perception of their overall
health (using the EuroQol 5-Dimension [EQ-5D] VAS [31]),
and previous use of health and fitness apps.
At 1 week and 1 month, patients were asked in a telephone
interview about their adherence to inhaled controller medication
during the previous week (on a 0 to 100 scale) and their asthma
control with CARAT. At 1 month, they were asked to rate the
app usability using 4 items of the System Usability Scale (ease
of use, function integration, confidence in using, would use
frequently) [32]. Patients were also asked about their general
satisfaction with the app and app components (gamification,
peer support, symptom monitoring, medication detection tool,
adherence monitoring), their willingness to recommend the app
to others, and the impact of the app on the motivation to adhere
to the inhaler. All these satisfaction questions were assessed
using a 1 (low) to 5 (high) scale. Patients were asked open
questions on the most and least preferred app features and asked
to make suggestions for app improvements. These telephone
interviews could also provide support regarding any technical
issues with the app or study-related doubts. Nonscheduled
telephone contacts could also occur, as patients were provided
with email and telephone contacts to use in case of any app
technical issue; this was rarely used. Interviews were performed
by a central team of trained health professionals and lasted
around 15 minutes. An interview guide was used to standardize
data collection across all patients.
Data Analysis
Descriptive statistics were used to characterize the sample and
app use. The normality of each variable was investigated with
Kolmogorov-Smirnov tests and visual analysis of histograms.
The app use rate was taken as the ratio between the number of
days with app use and the period of use (31-day period).
Adherence to medication measured by the app was calculated
using 2 methods: considering the medication taken only on days
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with app use and considering the medication taken regardless
of app use (ie, considering all medication scheduled for the
31-day period). Comparison of the characteristics of patients
installing the app versus those not installing, using the app for
more than 1 day versus single-day use, completing the study
versus dropouts, and adolescents versus adults were performed
using independent samples t tests, Mann-Whitney U tests for
continuous variables, and chi-square tests for categorical
variables. A Fisher test was used to compare adherence to
inhalers measured by the app with patient self-reports (at the
initial visit, 1 week, and 1 month). The Wilcoxon test and
McNemar test were used to analyze differences in CARAT total
score and CARAT control classification, respectively. Statistical
analyses were performed using SPSS (version 26.0, IBM Corp)
and plots were created using GraphPad Prism (version 6.0,
GraphPad Software). The level of significance was set at .05.
A thematic qualitative analysis of patient feedback (ie, opinions,
suggestions) about the app collected during the 1-month
telephone interview was also conducted. Notes from the
interviews were read, and emerging themes were grouped.
Description of patient feedback in major themes is supported
with translated representative statements.
Results
Participants
A total of 107 patients were included: 77 from 24 Portuguese
centers and 30 from 2 Spanish centers. Patients included mostly
adults (77/107; 72.0%) and females (63/107; 58.9%). Most were
on inhaled corticosteroid/long-acting beta-agonist combination
therapy (90/107; 84.1%) and used only one inhaler (67/107;
62.6%). Based on GINA classification, almost half (52/107;
48.6%) of the participants did not have their asthma well
controlled. Characteristics of the participants are shown in Table
2.
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Table 2. Participant baseline characteristics (n=107).
App used >1 day
(n=74)
App used 1 day
(n=25)
Did not install app
(n=8)
Total (n=107)Characteristic
26.5 (17-39)22 (16-40)40 (28-46)27 (17-40)Age (years), median (P25-P75a)
54 (73)15 (60)8 (100)77 (72.0)Adults, n (%)
47 (64)10 (40)6 (75)63 (58.9)Female, n (%)
22.8 (21-26)24 (22-29)26.2 (22-27)23.1 (21-27)BMI (kg/m2), median (P25-P75)
Smoking status, n (%)
57 (77)17 (68)5 (63)79 (73.8)Never smoker
11 (15)5 (20)3 (37)19 (17.8)Ex-smoker
6 (8)3 (12)09 (8.4)Current smoker
Inhaled medication, n (%)
61 (82)23 (92)6 (75)90 (84.1)ICSb/LABAc
14 (19)9 (36)3 (38)26 (24.3)SABAd
10 (14)2 (8)1 (13)13 (12.1)ICS
9 (12)1 (4)010 (9.3)LAMAe
48 (65)15 (60)4 (50)67 (62.6)Single inhaler, n (%)
85 (65-90)79 (53-90)83 (59-91)80 (60-90)VASf self-reported inhaler adherence (0-100)g
40 (54)7 (28)4 (50)51 (47.7)High (81-100), n (%)
22 (30)12 (48)3 (38)37 (34.6)Medium (51-80), n (%)
10 (14)4 (16)1 (12)15 (14.0)Low (0-50), n (%)
99.5 (90-100)90 (80-100)92.5 (89-99)99 (90-100)VAS correctness of inhaler technique (0-100)
34 (46)8 (32)042 (39.3)Oral medication, antileukotriene, n (%)
12 (16)5 (20)2 (25)19 (17.8)Allergen immunotherapy, n (%)
7 (9)1 (4)08 (7.5)Biologic therapy, n (%)
GINAh assessment symptom controli, n (%)
39 (53)11 (44)3 (38)53 (49.5)Well controlled
35 (47)13 (52)4 (50)52 (48.6)Partly controlled/uncontrolled
21 (17-24)20 (16-22)14.5 (9-27)21 (17-23)CARATj total score, mean (SD)
30 (41)16 (64)6 (75)52 (48.6)≥1 exacerbation past year, n (%)
15 (20)10 (40)2 (25)27 (25.2)≥1 unscheduled medical visit past year, n (%)
82 (70-90)75 (65-85)80 (58-89)80 (70-90)EQ-5Dk VAS, mean (SD)
11 (15)8 (32)4 (50)23 (21.5)First medical visit, n (%)
41 (55)12 (50)5 (63)58 (54.2)Previous use of health and fitness apps, n (%)
aP25-P75: percentile 25 to percentile 75.
bICS: inhaled corticosteroid.
cLABA: long-acting beta-agonist.
dSABA: short-acting beta-agonist.
eLAMA: long-acting muscarinic receptor antagonist.
fVAS: visual analog scale.
g4 missing values.
hGINA: Global Initiative for Asthma.
i2 missing values.
jCARAT-T: Control of Allergic Rhinitis and Asthma Test total score.
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kEQ-5D: EuroQol 5-Dimension test.
App Use
In total, 92.5% (99/107) of patients installed the app. The 8
patients who did not install the app were more frequently in a
first medical appointment with that physician (P=.02) and tended
to be older (P=.05) than those who installed the app. No other
significant differences were observed between the 2 groups.
More than half (64/99; 65%) of patients installed the app on the
recruitment day or the following day (median 0 [P25-P75 0-5];
Figure 2).
Figure 2. Percentage of users installing the app per study day.
Patients interacted with the app a median of 9 (P25-P75 1-24)
days: 25% (25/99) only 1 day and 10% (10/99) all 31 days
(Figure 3). A median use rate of 29% (P25-P75 3%-77%) was
observed. Patients interacting only 1 day were more frequently
male (P=.04), had a worse perception of their health status
(P=.045), and had more exacerbations in the previous year
(P=.04) in comparison with patients interacting more than 1
day. Although not reaching statistical significance, these patients
had a higher need for unscheduled medical visits in the previous
year (P=.05), more frequent short-acting beta-agonist prescribed
in their therapeutic plan (P=.09, physician-reported), and more
frequent depression symptoms (P=.09).
A total of 78% (77/99) of patients scheduled medication in the
app (median 2 [P25-P75 1-3] medications) for 25 (P25-P75
17-31) days: 74% (73/99) registered at least 1 inhaler and 42%
(42/99) at least another medication (eg, pills, nasal spray). The
asthma therapeutic plan reported by the physician included a
median of 2 (P25-P75 1.8-2) medications. A total of 53%
(52/99) of participants registered all prescribed inhalers and
34% (34/99) registered the complete asthma therapeutic plan
(inhaler and other drug formulations). Two (2%) patients also
used the app to register medications not related to asthma.
Median inhaler adherence assessed through the app was 81%
(P25-P75 58%-92%) when considering only days with app use
and 62% (P25-P75 23%-81%) when considering all scheduled
inhalations for the 31-day period (P<.001). Higher estimates
were observed when patients self-reported adherence at initial
visit (85 [P25-P75 63-90]), 1-week (95 [P25-P75 80-100]) and
1-month (100 [P25-P75 90-100]) interviews (P<.001; all
pairwise comparisons P<.009 with exception of 1-week and
1-month interview that were not different). Median adherence
for other drug formulations was 83% (P25-P75 50%-94%) when
considering only days with app use and 73% (P25-P75
26%-94%) when considering all scheduled inhalations for the
31-day period (P<.001).
A total of 17% (17/99) registered the use of relief medication
for at least 1 day (median 1 [P25-P75 1-2]): 13% (13/99) used
inhalers, 4% (4/99) other drug formulations (pills, nasal spray),
and 1% (1/99) inhaler plus others. During these episodes,
symptom severity reached a median VAS of 43 (P25-P75
29-60), with 2% (2/99) of patients reporting emergency
department visits and 1% (1/99) an unscheduled medical
appointment.
A total of 63% (62/99) of patients answered symptom
questionnaires: 62% (61/99) answered at least one CARAT
(median 1 [P25-P75 1-2]), 58% (57/99) answered weekly
symptom questionnaires (median 4 [P25-P75 2-4]), and 42%
(42/99) answered daily symptom questionnaires (median 9.5
[P25-P75 4-13.3]). A total of 76% (75/99) received at least one
badge (2 [P25-P75 2-3]), 63% (62/99) achieved 1000 points,
and 21% (21/99) achieved 10,000 points. A total of 6% (6/99)
of users became Inspirers, a role achieved between 5 and 28
days of app use.
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Figure 3. Daily participant engagement with the InspirerMundi app (n=97, 2 users with missing information). Each dot represents a day with interaction,
and each color represents a participant.
App Satisfaction
A total of 74% (79/107) of patients completed the 1-month
interview (28/107; 26% dropout rate). After 1 month, CARAT
scores improved (21 [P25-P75 16-23] vs 25 [P25-P75 22-27];
P<.001), with the proportion of patients with controlled asthma
increasing from 20% (16/79) to 53% (42/79; P<.001). Patients
were globally satisfied with the app, with 75% (59/79) scoring
≥4 on a 1 to 5 scale (33% [26/79] scored 4 and 42% [33/79]
scored 5), with the adherence monitoring, symptom monitoring,
and gamification being the most highly scored components
(Figure 4). Only 14% (11/79) were not satisfied with the app
(score ≤2). Patients found the app easy to use, considered the
functions well integrated, felt confident using the app, and would
like to use it frequently. A total of 77% (61/79) of patients would
recommend the app to other patients, and 53% (42/79) believed
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the app had motivated them to improve adherence to inhaled
medication. In general, adolescents were more satisfied with
the app than adults (Figure 4).
Figure 4. App feedback from adolescents and adults (n=79). Data are presented as box plots (lines inside the boxes represent the medians; bounds of
boxes, first and third quartiles; bars, 95% confidence interval). *Significant differences between adolescents and adults.
App Features Feedback
All patients provided feedback on the app, 95% (75/79) pointed
out the aspects that they valued most, 73% (58/79) mentioned
aspects least preferred, and 62% (49/79) made improvement
suggestions. Patient feedback was reflected in 4 major themes:
medication-related features (67/79, 85%), gamification and
social network (33/79, 42%), symptom monitoring and physician
communication (21/79, 27%), and other aspects (16/79, 20%).
These themes are described in detail below.
Medication-Related Features
Patients pointed out the notifications for the medication (47/79,
59%) and adherence statistics (18/79, 23%) as strengths of the
app. Yet 2 patients reported problems in receiving notifications,
and 2 suggested improvements such as making notifications
clearer, sending a second notification if the medication was not
taken within 1 hour, and allowing the confirmation of
medication intake without entering the app. The available time
to confirm the medication intake (2 hours after the notification)
was considered inflexible (13/79, 16%) as it did not allow for
confirmation if the medication was taken earlier (before the
notification) or later. This was seen as a disadvantage as it
compromised the game and adherence statistics. Patients asked
for the possibility to also confirm medications when outside of
scheduled hours (15/79, 19%).
[Notifications] It helped me to remember to take the
medication.
With the adherence statistics, I have a better
perception of my real adherence.
I lost points because I took the medication out of the
scheduled hours, and I was not able to confirm it.
The need to use the medication detection tool to confirm each
medication intake was seen as a weak point (22/79, 28%),
mainly due to the predefined time to capture the image,
perceived as long. This was especially burdensome for patients
with more complex medication regimens (eg, more than one
control medication per day). Patients suggested that the
medication detection tool could be faster in detecting the dose
counter (5/79, 6%), provide feedback of the identified number
(2/79, 3%), and be activated only at certain time points (eg,
every 5 days or with personalized frequency; 4/79, 5%). Two
patients would like the app to include educational content related
to asthma and inhalation technique.
The time I need to wait for the app to take the picture
of the inhaler...
There could be an option that allows you not to have
to take a photo of the inhaler daily, but to take it, for
example, on the first day and after 5 or 7 days.
The app could include a demonstration on how to use
the inhaler using images.
Registration of controller or relief medication was reported as
difficult by 4 patients and they asked for a simpler process,
suggesting, for example, selecting the medication from a
provided list, not needing to insert a new medication when a
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new inhaler is bought, and personalizing scheduled times
depending on the day of the week (eg, during weekends).
I found it difficult to register an SOS intake; I need
more information to be able to use this feature.
When the inhaler is over, it would be nice not to have
to register a new inhaler with all the data.
Gamification and Social Network
Opinions differed with regard to the gamification and social
network components: 18% (14/79) of patients (both adolescents
and adults) were happy and stated that these components were
an additional motivation to improve adherence; 13% (10/79, 9
adults) felt these components were unnecessary or not adding
benefit. Two patients reported the gamification approach as
confusing, and others did not like the Inspirers avatar.
The game increases my motivation to take the
medication.
I don’t have any interest in using the game or to share
experiences in the social network.
Symptom Monitoring and Physician Communication
Patients pointed out the advantages of symptom monitoring
(10/79, 13%), with three acknowledging that it increased their
perception of disease control (n=3). Three patients also
highlighted the utility of the app to share clinical information
(use of relief medication, symptoms) with the physician (n=3).
One patient suggested a more direct connection with the
physician through a chat, for example, to receive
recommendations, clarify doubts, and even schedule
appointments, and another suggested the addition of features
to compare symptom evolution.
I liked the symptom questionnaire and interpretation.
The questionnaires were simple to fill in.
The possibility to have a reliable registration of my
disease trajectory and to be able to show to a health
professional. I hope to have benefits with this
registration!
It would be good to chat with my physician, clarify
doubts, and schedule appointments.
I would like to compare the results of the
questionnaires to be able to notice if there was any
improvement in symptoms or not.
Others
Patients reported experiencing technical difficulties/bugs (during
log-in, registration of symptom questionnaires, medication
detection tool; sometimes the app crashed or closed
unexpectedly [8/79, 10%]) and two patients reported that the
app used significant storage space (n=2). Other suggestions
were a timeline showing the present events by default, simplified
log-in (eg, touch ID), and improved access to Definitions and
Profile menus.
The app could be smaller.
Log-in could be simplified, and could be with
smartphone biometry.
App Changes Based on Patient Use and Feedback
Based on patient feedback, two major changes were
implemented in a new Android app (version 1.2): redesign of
the therapeutic plan registration module and medication
detection tool. Now, to register an inhaler, the patient is provided
with images of the most common inhalers available on the
Portuguese and Spanish markets and once the patient selects
the inhaler type, a drop-up list presents all names/dosages of
medications available on the market. The patient can also select
different schedules on different days, allowing the
personalization requested. To allow the registration of the
complete asthma therapeutic plan, the patient can indicate if the
controller inhaler can also be used as relief and how many
inhalations are recommended in that case. Also, as registering
medications is the only way the app produces notifications, this
is now the first task asked once the patient enters the app.
When a medication is due, notifications provide information
on the medication and posology and the patient can select 1 of
3 options: confirm medication was taken, delay medication
intake (from 5 to 120 minutes), or decide not to take it. Patients
now have until the end of the day to confirm medication was
taken. The medication detection tool is currently able to detect
12 inhaler devices containing numeric dose counters available
on the Portuguese and the Spanish markets. The medication
detection tool is activated daily only for inhalers (not for other
drug formulations) to reduce the users’burden. When the patient
confirms medication was taken, an initial screen with
instructions on how to match the inhaler with the template is
provided, but in the current version instead of an example figure,
we use a short video demonstrating the task (patients can decide
to inactivate these instructions whenever they want to accelerate
the process). A feature to provide feedback on the identified
number in the inhaler was already developed [16] allowing the
user to correct the number, and it will be introduced in a future
app version. Reasons for deciding not to take a medication can
also be registered (eg, medication is empty, this dose is not
needed, secondary effects). Screenshots with these app changes
are presented in Figure 5, and videos are available [33,34].
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Figure 5. InspirerMundi app screenshots (version 1.2).
Discussion
Principal Findings
The InspirerMundi app was found to be feasible to monitor
medication adherence and positively evaluated by patients with
persistent asthma. The results of this study provide an
understanding of the feasibility and acceptability of this mHealth
technology in this population. The study contributed to identify
improvements for a better user experience before effectiveness
studies are undertaken.
Patient use rate of the app is similar to a previous mHealth
asthma observational study (median of 12 days in the first 3
months) [35,36], and it is within the range described in digital
health studies (median 6 days, range 2 to 26, in the first 3
months) [36]. Nevertheless, we consider the patient use rate
lower than expected as the app was directly recommended by
a physician and app use was reinforced by 3 text messages and
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a telephone interview. This low engagement may be linked to
the real-world nature of these studies and the low previous use
of asthma apps (<5%) [13]. Importantly, it may also be related
to the low level of maturity of some of the app technologies.
Less than one-third of patients interacted with the app only 1
day, which is lower than previously described behaviors [36].
These patients were found to be the ones with worst asthma
outcomes, such as unscheduled medical visits and exacerbations,
and worst perception of health status. Chan et al [35] also
observed that the group of patients with fewer interactions with
an asthma app were the ones with higher hospitalization rates
and emergency department visits. Male patients were also
associated with lower interaction, in accordance with previous
observations of male patients to be less likely to adopt health
apps [37]. These observations need to be considered in the
design of mHealth-based interventions to improve adherence
to medications.
A small proportion of patients entered the study but did not
install the app (8%), which is in line with previous studies with
asthma apps [38]. It was not surprising to observe that these
patients were older and most commonly were in a first medical
appointment. In fact, older patients are the least represented in
digital health studies [36,39] and are also less likely to adopt
health apps [37]. First appointments with a health care provider
are linked to a greater discordance between patients and
physicians [40], which may contribute to reducing the known
role of physician recommendation as a facilitator of mHealth
adoption [36,41]. The total dropout rate (26%) is in accordance
with rates in feasibility studies with digital interventions [42]
but higher than previously described in clinical trials [38]. This
dropout rate was expected given the real-world nature of the
feasibility study involving patients from a large number of
secondary care centers (26 in total), very diverse in terms of
settings—secondary and tertiary care, public and privately
owned, dimension, geographic regions, and medical specialties
(allergy, pulmonology, and pediatrics). This is contrasted with
clinical trials, which are most often conducted in well-selected
academic centers with more homogeneous samples and a high
number of face-to-face visits.
More than three-quarters of patients used the app for medication
management and adherence monitoring, which were the primary
aims of app use, and a median score of 4 out of 5 was obtained
for this app feature. Self-reported inhaler adherence at the initial
visit, 1-week and 1-month interview overestimated adherence
measured with the app. This was somewhat expected as
self-reports had a near to perfect treatment adherence behavior,
which is unlikely to be the case [40]. Overestimation of
adherence measured by the app is also possible, as no objective
confirmation of the inhaler dose counter was performed in this
version. New versions of the app should assess inhaler adherence
more objectively by validating inhaler use through dose tracking.
The medication detection tool is currently working with 13
inhaler devices containing numeric dose counters available on
the Portuguese and Spanish markets [16]. To improve the
generalizability of the app and its use in multicenter international
studies, inhalers available in other countries will be added in
future versions of the app.
Patient evaluations were positive: three-quarters were globally
satisfied (75%), reporting scores of 4 (33%) and 5 (42%). The
InspirerMundi app acceptability was similar to that described
in other feasibility studies of mHealth apps [43-45].
Notifications for medication intake were considered helpful
[20,46]. Patients made important contributions for improvement
such as the need to make notifications clearer and registration
of medications easier. These requested changes are in line with
user reviews for other adherence apps [46] and were
implemented in the InspirerMundi Android version 1.2, currently
being tested by patients recruited at primary care centers.
Patients also suggested improvements to the medication
detection tool, which led to the tool’s redesign, including
feedback on the identified number.
Symptom monitoring, used by almost two-thirds of patients,
was one of the most highly scored components, with patients
stating that it increased their perception of asthma control [20].
Patients valued the feature of sharing information with physician
[20,46] and requested other patient-physician partnership tools.
In the tested version, patients could send data on the therapeutic
plan registered in the app and respective adherence to their
physician by email. New simple and easily read reports
(including graphs/charts) have been designed, and a tool for
remote personalized feedback is being planned. We believe
these upgrades will facilitate the integration of app data into
clinical workflow and strengthen the patient-physician
partnership.
Based on patient feedback, improvements on gamification,
social support and monitoring features, and integration of
educational content are needed to ensure ongoing digital
engagement. The team is considering the integration of new
gamification dynamics and mechanics (eg, avatar
personalization, progression bars, boosters, exchange points,
other tangible rewards), social support features (eg, discussion
forums, mentoring, group actions), and educational features
(eg, training videos on inhalation technique) [20]. There were
opposing opinions regarding the gamification and social network
components, also observed in a previous study with adolescents
with asthma [20]. To accommodate these differences, and as
personalized strategies to treatment adherence have better results
[47,48], gamification and social network features of the app
will become optional and patients not willing to use these
features will be able to turn them off. This modification is in
line with previous work advocating that flexible apps may better
meet the needs of a broader range of patients [49,50].
Limitations
This study has limitations. As a feasibility study, a control group
was not included, and the sample size was not powered. This
was a deliberate choice to test the feasibility and acceptability
of the app for the first time. As the study was conducted at
secondary care centers from Portugal and Spain, results may
not be generalized to other settings or countries. An updated
version of the app is being tested in Portuguese primary care
centers. Participation in the study was restricted to patients who
have access to a smartphone. Although smartphones are
increasingly prevalent in patients with asthma [13], this
requirement excluded otherwise eligible patients and limits the
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generalizability to smartphone owners. Using an app to improve
treatment adherence will not be a solution for all patients, as
happens with most, if not all, approaches. With this study,
previous ones, and others planned it should be possible to
identify those patients who may benefit from InspirerMundi
app strategies. The use of two methods to calculate medication
adherence may also be seen as a limitation of the study, yet it
was a mitigation plan to overcome the absence of a standardized
method to measure adherence [9].
Conclusion
In conclusion, the InspirerMundi app was feasible and
acceptable to monitor medication adherence in adolescents and
adults with asthma. Based on patient feedback, redesign of the
therapeutic plan registration and the medication detection tool
have already been implemented, and other changes to the app
are being considered. This study is part of a continuous
development cycle that will continue with its multiple
improvement and evaluation phases grounded on the interaction
with end users, aiming to produce a patient-centered and
engaging mHealth asthma app.
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